Bortezomib D-mannitol

Star1

DB16741ApprovedInvestigationalSmall moleculeProteasome Inhibitors

Bortezomib D-mannitol: Overview.

Mechanism: Pharmacologically active on Proteasome subunit beta type-5
Curator reviewed
Formula / weight: C₂₅H₃₅BN₄O₈ · 530.39 g/mol (avg)
First approval: Canada, 2005
Also known as: Bortezomib D-mannitol ester · Bortezomib D-mannitol symmetrical ester · Bortezomib mannitol boronic ester
Brand names: Velcade

Resolves to

Compound

UNIIP2AWN9VSQ6CAS444576-08-3

Structure

InChIKeyQDMRNLRJDHCHLB-DNNBANOASA-NSMILES[H][C@@]1(OB(O[C@]1([H])[C@H](O)CO)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=NC=CN=C1)[C@H](O)CO

Targets

P28074PSMB5

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

38Drug interactionsStructured to mechanism, not free text

17Clinical trialsPhase, status and sponsor resolved per trial

24Marketed productsAcross 1 country and 14 labellers

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Bortezomib D-mannitol, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account